American Journal of Kidney Diseases
Volume 45, Issue 1 , Pages 102-111, January 2005

Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation

  • Nelson Leung, MD

      Affiliations

    • Division of Nephrology, Mayo Clinic, Rochester, MN, USA
    • Corresponding Author InformationAddress reprint requests to Nelson Leung, MD, Department of Medicine, Division of Nephrology, Mayo Clinic, 200 First Street SW, Eisenberg SL-24, Rochester, MN 55905.
  • ,
  • Jeff M. Slezak, MS

      Affiliations

    • Division of Biostatistics, Mayo Clinic, Rochester, MN, USA
  • ,
  • Erik J. Bergstralh, MS

      Affiliations

    • Division of Biostatistics, Mayo Clinic, Rochester, MN, USA
  • ,
  • Angela Dispenzieri, MD

      Affiliations

    • Department of Pharmacy, Mayo Clinic Rochester, MN, USA
  • ,
  • Martha Q. Lacy, MD

      Affiliations

    • Department of Pharmacy, Mayo Clinic Rochester, MN, USA
  • ,
  • Robert C. Wolf, PharmD

      Affiliations

    • Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • ,
  • Morie A. Gertz, MD

      Affiliations

    • Department of Pharmacy, Mayo Clinic Rochester, MN, USA

Received 23 February 2004; accepted 16 September 2004. published online 29 November 2004.

Background: Patients with primary systemic amyloidosis (AL) have a poor prognosis. Median survival time from standard treatments is only 17 months. High-dose intravenous melphalan followed by peripheral blood stem cell transplant (PBSCT) appears to be the most promising therapy, but treatment mortality can be high. The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning. This study was undertaken to further examine its risk factors and impact on posttransplant mortality. Methods: Consecutive AL patients who underwent PBSCT were studied retrospectively. Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 μmol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning. Urine sediment score was the sum of the individual types of sediment identified on urine microscopy. Results: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan. Univariate analysis identified age, hypoalbuminemia, heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors. Age and urine sediment score remained independently significant risk factors in the multivariate analysis. Patients who had ARI after high-dose melphalan underwent dialysis more often (P = 0.007), and had a worse 1-year survival (P = 0.03). Conclusion: The timing of renal injury strongly suggests melphalan as the causative agent. Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment. Development of ARI adversely affected the outcome after PBSCT. Effective preventive measures may help decrease the treatment mortality of PBSCT in AL patients.

Index words:  Primary amyloidosis , nephrotic syndrome , renal insufficiency , peripheral blood stem cell transplant (PBSCT) , melphalan , urine sediment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0272-6386(04)01314-9

doi:10.1053/j.ajkd.2004.09.015

American Journal of Kidney Diseases
Volume 45, Issue 1 , Pages 102-111, January 2005